AI to Augment, Not Replace, Medical Decision-Making, Says Tehran Medical University President at INOTEX 2026

During a session at the Iran International Innovation & Technology Exhibition (INOTEX), Khoshdel outlined the transformative potential and ethical boundaries of artificial intelligence in healthcare. According to the INOTEX 2026 News Center, integrating AI can significantly reduce drug development timelines by up to 3.5 years, saving an estimated $15 million per day of delayed market entry.

Key insights and strategic imperatives highlighted include:

• Accelerated Drug Development: Leveraging AI to streamline research and development, mitigating massive financial losses associated with delayed pharmaceutical launches.
• The Three Pillars of Treatment: Emphasizing that effective medical care integrates medical knowledge, the physician's clinical experience, and the patient's personal circumstances, beliefs, and economic conditions.
• Ethical and Contextual Limits: Noting that while AI can process vast datasets, it cannot fully comprehend the nuanced, human-centric factors essential for holistic medical decision-making.
• Enhanced Precision and Efficiency: Acknowledging that AI, alongside the Internet of Things (IoT), makes medical procedures faster, more accurate, cost-effective, and highly reproducible.

Khoshdel concluded that the future of healthcare lies in a synergistic approach, where advanced technologies augment human expertise rather than replace the fundamental doctor-patient dynamic.

CMS Hashtags: #INOTEX2026 #ArtificialIntelligence #HealthTech #MedicalInnovation #DigitalHealth